More Info
									                                          P R E S I D E N T ’ S                      M E S S A G E

                  Nadine Nakazawa, RN, BS, OCN

         y the time this column is published, we will be con-          volumes, chlorhexidine impregnated dressings, coated cathe-
         vening our annual conference. This has been a difficult        ters), but we do not have adequate technologies or strategies to
         and challenging year economically for our country, and        prevent or manage intraluminal microbial colonization. There
severe cutbacks in all areas have been experienced. With job           are a number of antimicrobial locks in clinical trials and we
losses, comes loss of health insurance and the ranks of the un-        anxiously await these results. Will they be as efficacious as we
insured continue to climb. College graduates are experiencing          hope? Will they be easy to use across the continuum of care?
one of the most challenging job markets in decades, and jobs           Will they be affordable?
with health care benefits are scarce.                                      We are seeing increasing focus on venous thrombosis, the
   We have seen IV and PICC teams getting their positions and          damage to the vasculature that occurs with repeated insertions
budgets slashed, and adequate vascular access becomes ever             of central venous access devices, and poor tip placements. The
more challenging in our most seriously and chronically ill pa-         next wave of technology is to bring tip navigation systems from
tients. There are a number of national initiatives focusing on         avoiding obvious malpositions to more accurately identifying
reducing “errors” in healthcare, putting needed attention on           the lower one third of the superior vena cava, near the caval-
vascular access. It is unfortunate that pressure has to be placed      atrial junction. We anxiously await the results of the clinical
on healthcare systems in a negative way in order to get the fo-        trials of a number of innovative and advancing technologies.
cus and attention on our area of specialty.                               There remain many questions about what the best practice is
   In response to identified vascular access issues, we see on the      with vascular access. We encourage you to ask the key ques-
horizon innovative technologies that will help address some
To top